JPRN-jRCT2080223489已完成3 期
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Subjects who have qualified for and received investigational product (anifrolumab or placebo) and completed the treatment period in Studies D3461C00004 or D3461C00005 (through Week 52)
- •2. Adequate peripheral venous access
- •3. Females with an intact cervix should have documentation of a Pap smear with no documented malignancy within 90 days before Day 1/Visit 1 or 30 days following Day 1/Visit 1. Since access to a Pap smear may vary by country, the Sponsor recommends that local guidelines for obtaining Pap smears in subjects who have received immunomodulators or immunosuppressive treatment be followed.
- •4. Meets the following TB criteria:
- •a. Negative QuantiFERON-TB Gold [QFT-G] test result for TB obtained from the study central laboratory at Week 52 of Studies D3461C00004 or D3461C00005;
- •b. Newly positive QFT-G test result at Week 52 of Studies D3461C00004 or D3461C00005 from the study central laboratory. A chest x-ray must be performed. If the chest x-ray shows no evidence of active TB, and the subject has no symptoms or medical history consistent with active TB, the subject must have a retest. If the retest is positive, the subject must start on prophylaxis within 30 days of randomisation but prior to the second dose of investigational product (Visit 2/Week 4);
- •c. Positive but not newly positive QFT-G test at Week 52 of Studies D3461C00004 or D3461C00005. The subject must have been diagnosed with latent TB and must have documentation confirming initiation of appropriate treatment OR initiate treatment for latent TB within 30 days of randomization, but prior to the second dose of investigational product administration (Visit 2/Week 4)
- •d. Newly indeterminate (confirmed on retest) or indeterminate but not newly indeterminate QFT-G test result at Week 52 of Studies D3461C00004 or D3461C00005 from the study central laboratory with ongoing QFT-G testing for TB according to the Study Plan
- •5. In the opinion of the Investigator, subject must be able to comprehend the ICF and all protocol related assessments
排除标准
- •1. Receipt of any of the following within the last 60 days:
- •a. Azathioprine >200 mg/day
- •b. Mycophenolate mofetil/mycophenolic acid >2.0 g/day
- •c. Oral, subcutaneous, or intramuscular methotrexate >25 mg/week
- •The SOC used at study sites will be in line with local labels and local treatment practice in the relevant country/region.
- •2. Receipt of any investigational product (small molecule or biologic agent other than anifrolumab) within 4 weeks or 5 half-lives prior to Day 1/Visit 1, whichever is greater
- •3. Receipt of any of the following:
- •a. Any live or attenuated vaccine within 8 weeks prior to Day 1/Visit 1 (administration of killed vaccines is acceptable, the Sponsor recommends Investigators ensure all subjects are up to date on required vaccinations, including influenza [inactivated/recombinant] vaccine prior to study entry)
- •b. Bacillus Calmette-Guerin (BCG) vaccine between the end of Studies D3461C00004 or D3461C00005 and Day 1/Visit 1
- •4. Active severe SLE-driven renal or neuropsychiatric disease
- •5. Any underlying condition that predisposes the subject to infection, including history of/current human immunodeficiency virus (HIV) infection
- •6. Subjects with Hepatitis B core antibody (HBcAb) positivity at enrolment of Studies D3461C00004 or D3461C00005 will be tested every 3 months for Hepatitis B virus (HBV) DNA. To remain eligible in the LTE study, subject HBV DNA levels must remain below the lower limit of quantitation (LLOQ) as per the central laboratory.
- •7. Opportunistic infection requiring hospitalisation or parenteral antimicrobial treatment within 3 years of Day 1/Visit 1
研究者
相似试验
进行中（未招募）
1 期
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus ErythematosusMedDRA version: 19.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2016-000625-39-ESAstraZeneca AB547
进行中（未招募）
1 期
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus ErythematosusMedDRA version: 20.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2016-000625-39-HUAstraZeneca AB575
进行中（未招募）
1 期
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2016-000625-39-LTAstraZeneca AB575
进行中（未招募）
1 期
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus ErythematosusMedDRA version: 20.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2016-000625-39-BGAstraZeneca AB547
进行中（未招募）
1 期
A study to characterize the safety and tolerability of Anifrolumab in adult patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2016-000625-39-DEAstraZeneca AB575